1. Analysis of payments to GI physicians in the United States: Open payments data study
- Author
-
Swathi Talla, Rajan Amin, Amarnath Annapureddy, Praveen Kanneganti, Venu Gopala Reddy Gangireddy, and Kevin Yu
- Subjects
Actuarial science ,Hepatology ,business.industry ,Leading Articles ,media_common.quotation_subject ,gastroenterology ,Payment ,compensation ,03 medical and health sciences ,0302 clinical medicine ,Physician payment ,Leading Article ,payment ,030220 oncology & carcinogenesis ,Financial transaction ,affordable care act ,Health insurance ,Medicine ,030211 gastroenterology & hepatology ,business ,Medicaid ,health care economics and organizations ,media_common - Abstract
Background and Aim The purpose of this study was to review and analyze the nature of industry payments to gastroenterology and hepatology (GI) physicians. Methods We conducted a retrospective study of open payments (OP) data for the year 2017. Payments to individual physicians were aggregated using a unique physician profile identification number. General payments to Centers for Medicare and Medicaid Services regions were also analyzed. The nature of financial transactions in general payments was reported overall and per physician payment. Research, ownership, and general payments were aggregated and analyzed by drug/device companies. Results During the study period, more GI physicians received contributions in the form of general payments compared to ownership or research payments. A small percentage of physicians received contributions greater than $100 000. The most frequent contributions were for food and beverages. Only 10 manufacturers made about 71% ($43 271 938) of general payments. Conclusions We found that only a small number of GI physicians received a significant portion of industry payments. A large portion of those payments came from drug or device companies. The impact of these payments on gastroenterologists needs to be examined further., We found that only a small number of GI physicians received a significant portion of industry payments. A large portion of those payments came from drug or device companies. The impact of these payments on gastroenterologists needs to be examined further.
- Published
- 2020